{"name":"StemCyte Taiwan Co., Ltd.","slug":"stemcyte-taiwan-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"hUCB","genericName":"hUCB","slug":"hucb","indication":"Hematologic malignancies (leukemia, lymphoma, myeloma) as alternative to bone marrow transplant","status":"marketed"}]}],"pipeline":[{"name":"hUCB","genericName":"hUCB","slug":"hucb","phase":"marketed","mechanism":"hUCB is a human umbilical cord blood-derived cell therapy that provides hematopoietic and immunomodulatory support for hematologic reconstitution and immune recovery.","indications":["Hematologic malignancies (leukemia, lymphoma, myeloma) as alternative to bone marrow transplant","Bone marrow failure syndromes","Severe aplastic anemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxPX0c3dUE4ZmdDQlM5c2U5Y0xMeWdMOHJxNWV4cGl1SWd3aXZ1UTIzWTY1V1ZvTkxhSzV3cGxyQnVqRmxGR3Y3MV8zekxtYjc0X1JxSldOZmR5RnBqaUltN21nbUgycFhUajFxOGJqTEVQR3VfN2dkY3NicWl3SlB5TF8yeHpHbTNmblVtb19lTWV4NHdfNjhabnRTdFo0aHYtaE9NX1kwanktdjFNU0dCbXNHTVlIN1BkOFhVV3NkSVJGYTl6RG1Ta25RREt0Um1sYXRCMXNPTFlZejlwVUVpMTBadC14amhpSjgyS1p4WmJFbFRUQ2VqaTJ4OFQ1YWRMSkhtQU93THRPYmxIamc?oc=5","date":"2025-11-05","type":"pipeline","source":"prnewswire.com","summary":"StemCyte Launches First Insurance-Linked Public Cord Blood Access in Taiwan, Setting a New Standard in Cell Therapy Protection - prnewswire.com","headline":"StemCyte Launches First Insurance-Linked Public Cord Blood Access in Taiwan, Setting a New Standard in Cell Therapy Prot","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}